p53 silencing increases growth at metastatic sites. BC3-p53WT or BC3-p53KD cells were injected to the left cardiac ventricle (A, p = 0.22 at 4 weeks; p = 0.01 at 6 weeks)) or tail vein (B, p = 0.03 at 13 weeks), and mice were subjected to BLI in vivo at the indicated time points. Total photon flux was assessed on an IVIS SPECTRUM and quantified. Each data point represents one mouse. All error bars represent standard error of the mean (SEM). Wilcoxon rank sum tests were used for statistical analyses. (PDF 73 kb
Figure S3. Estrogen promotes Brca1-proficient and deficient mammary tumor initiation (A)Â Western bl...
Figure S3. Patient-derived xenograft. (A) Primary human TNBC was surgically removed and implanted wi...
Figure S4. (A and B) Real-time PCR of NANOG, BMI-1, SOX2 and OCT4 in the indicated cells. Transcript...
p53 silencing does not increase number of tumor-initiating cells. (A and B) Limiting numbers of BC3-...
CTC number correlates with mammary tumor size. Mouse mammary fat pads were engrafted with BC3-p53WT ...
Ectopic expression of BTG2 in BC3-p53KD cells reduces cell proliferation in vitro. BC3-p53KD cells w...
Mini-signature of genes that interact with the p53 pathway and associated p values. (PDF 62 kb
Pathway analysis of RNA-Seq expression signature consisting of genes deregulated upon p53 knockdown....
Figure S1. Wild-type p53 expression inversely correlates with HER2 mRNA levels. HeLa (A) and Saos-2 ...
Characterization of metastatic properties of Patient Derived Xenograft models after intracardiac inj...
Figure S2. Characteristics of the basal and luminal populations isolated from control and K5Cre;Trp5...
Figure S1. Molecular characteristics of the luminal subsets isolated from control and K5Cre;Trp53F/F...
Showing proliferation characteristics of mammary tumors from K14Crep53 F/F and K14CreERβ F/F 53 F/F ...
Figure S1. (A) Microscopy of EGFP-tagged p53-BakMTS, DBD-BakMTS, p53- BaxMTS, and DBD-BaxMTS constru...
Systemically infused MSCs persist in the lungs of the LoVo cancer cell-bearing mice. Five weeks afte...
Figure S3. Estrogen promotes Brca1-proficient and deficient mammary tumor initiation (A)Â Western bl...
Figure S3. Patient-derived xenograft. (A) Primary human TNBC was surgically removed and implanted wi...
Figure S4. (A and B) Real-time PCR of NANOG, BMI-1, SOX2 and OCT4 in the indicated cells. Transcript...
p53 silencing does not increase number of tumor-initiating cells. (A and B) Limiting numbers of BC3-...
CTC number correlates with mammary tumor size. Mouse mammary fat pads were engrafted with BC3-p53WT ...
Ectopic expression of BTG2 in BC3-p53KD cells reduces cell proliferation in vitro. BC3-p53KD cells w...
Mini-signature of genes that interact with the p53 pathway and associated p values. (PDF 62 kb
Pathway analysis of RNA-Seq expression signature consisting of genes deregulated upon p53 knockdown....
Figure S1. Wild-type p53 expression inversely correlates with HER2 mRNA levels. HeLa (A) and Saos-2 ...
Characterization of metastatic properties of Patient Derived Xenograft models after intracardiac inj...
Figure S2. Characteristics of the basal and luminal populations isolated from control and K5Cre;Trp5...
Figure S1. Molecular characteristics of the luminal subsets isolated from control and K5Cre;Trp53F/F...
Showing proliferation characteristics of mammary tumors from K14Crep53 F/F and K14CreERβ F/F 53 F/F ...
Figure S1. (A) Microscopy of EGFP-tagged p53-BakMTS, DBD-BakMTS, p53- BaxMTS, and DBD-BaxMTS constru...
Systemically infused MSCs persist in the lungs of the LoVo cancer cell-bearing mice. Five weeks afte...
Figure S3. Estrogen promotes Brca1-proficient and deficient mammary tumor initiation (A)Â Western bl...
Figure S3. Patient-derived xenograft. (A) Primary human TNBC was surgically removed and implanted wi...
Figure S4. (A and B) Real-time PCR of NANOG, BMI-1, SOX2 and OCT4 in the indicated cells. Transcript...